A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

Guy PrattChristina YapCeri OldreiveDaniel SladeRebecca BishopMike GriffithsMartin J S DyerChristopher FeganDavid OscierAndrew PettittEstella MatutesStephen DevereuxDavid AllsupAdrian BloorPeter HillmenGeorge FollowsSimon RulePaul MossTatjana Stankovic

Published in: British journal of haematology (2017)

Keyphrases

acute lymphoblastic leukemia
acute myeloid leukemia
dna damage
study protocol
diffuse large b cell lymphoma
phase iii
multiple myeloma
clinical trial
dna repair
randomized controlled trial
oxidative stress
open label